Skip to main content
. 2016 Oct 18;18(11):654–665. doi: 10.1016/j.neo.2016.09.004

Figure 2.

Figure 2

ASNS expression in CRC.

(A) Western blot analyses of HCT116 (left) and DLD-1 (right) treated with dimethyl sulfoxide (DMSO), 20 μM U0126 (MEK inhibitor), 50 μM LY294002 (PI3K inhibitor), or 20 nM rapamycin (mTOR inhibitor) for 48 hours. Protein levels were normalized to β-actin (Actin). Densitometry values were expressed as fold change compared with DMSO treating cells. (B) Western blot analysis of ASNS expression in several human CRC cell lines. Densitometry values were expressed as fold change compared with HCT116. (C) H&E and immunohistochemical staining for ASNS in primary CRCs. Upper panels show serial sections of a KRAS-mutant CRC case, whereas lower panels show those of a wild-type KRAS one. Scale bar, 50 μm. (D) Relationship between KRAS mutational status and ASNS expression in 93 primary CRC samples.